Status:
COMPLETED
The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Pseudotumor Cerebri
Cystinosis
Eligibility:
All Genders
2-50 years
Brief Summary
This study will examine whether the tendency to have thrombosis, or the formation of blood clots inside blood vessels, has a role in the development of pseudotumor cerebri (PTC). PTC causes symptoms a...
Detailed Description
During the follow-up of cystinosis patients under protocol #78-HG-0093 "Use of Cysteamine in the Treatment of Cystinosis", we found that 6 of our NIH patients developed papilledema and were diagnosed ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- The inclusion criteria include only a confirmed diagnosis of pseudotumor cerebri (past or present) in a patient with nephropathic cystinosis. Patients will be diagnosed as having pseudotumor cerebri based upon modified Dandy criteria:
- signs and symptoms related to increased intracranial pressure;
- no localizing neurological signs with the exception of unilateral or bilateral sixth nerve palsy;
- neuroimaging study showing no mass lesion or hydrocephalus;
- elevated opening pressure with normal cerebrospinal fluid contents on lumbar puncture.
- Nephropathic cystinosis patients of all ages who meet the Dandy criteria for PTC will be considered for the study.
- EXCLUSION CRITERIA:
- Pregnant patients will be excluded from the study.
Exclusion
Key Trial Info
Start Date :
October 30 2003
Trial Type :
OBSERVATIONAL
End Date :
July 18 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00071903
Start Date
October 30 2003
End Date
July 18 2008
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892